Google DeepMind's AlphaFold 3 has achieved 95% accuracy in predicting drug-protein interactions, a breakthrough that could cut pharmaceutical R&D timelines by years and save billions in development costs.
The Advance
AlphaFold 3 can now model how drug molecules interact with target proteins and predict side effects before any physical testing begins. Pharmaceutical companies have begun integrating it into their discovery pipelines.
Impact on Drug Development
Pfizer, Novartis, and Roche have all licensed AlphaFold 3 for drug development. Analysts estimate it could reduce the average drug development timeline from 10 years to 5-6 years.
- 95% accuracy in drug-protein interaction prediction
- Could halve drug development timelines
- Pfizer, Novartis, Roche licensing the technology
- Side effect prediction before physical testing
